Brow lifts top the list of facial enhancements, increasing by 27%, while eyelift surgery is up by 8% and face and neck lifts have risen by 11%, according to BAAPS data. Breast augmentation remains the UK's most popular cosmetic surgery, but procedures have declined by 8%, the data shows. Superficial Gluteal Lipofilling (SGL) surgeries have plummeted by 38%, according to BAAPS.
6 million UK adults were on some form of weight-loss drug from early 2024 to early 2025, which may be influencing these trends. According to Metro, Rajiv Grover described Ozempic face as driving medical reasons for patients seeking facial aesthetic procedures. Ozempic face is a phenomenon referring to sagging, ageing, and lacklustre appearance of the facial skin and structures due to rapid weight loss, according to Dr Adil Sheraz, a consultant dermatologist and British Skin Foundation spokesperson.
According to Metro, Dr Adil Sheraz described how rapid loss of subcutaneous facial fat from weight-loss drugs can lead to sagging skin that cannot shrink at the same rate. He noted that Ozempic face may be more of an issue in older individuals due to reduced collagen and elastin in the skin. The term 'Ozempic face' references the off-brand use of the drug by people without type 2 diabetes for weight loss.
Novo Nordisk, the manufacturer of Ozempic, could not comment on 'Ozempic face' specifically in 2024 due to its off-brand use reference. According to Metro, Dr Paul Jarrod Frank described frequently identifying patients on Ozempic based on their sudden need for facial filler. 6 million UK adults on weight-loss drugs are specifically using Ozempic, Mounjaro, or Wegovy.